Azadyne - About the company
Azadyne is a seed company based in Kent (United Kingdom), founded in 2017 by Vincent Kelly, Mike Southern and Stephen Connon. It operates as a Provider of therapeutic for autoimmune disease. Azadyne has raised $1.97M in funding from NCL. The company has 1970 active competitors, including 448 funded and 319 that have exited. Its top competitors include companies like Antheia, Transcenta and Akeso.
Company Details
Azadyne is a spin-out company from Trinity College Dublin and involved in the development of therapies for autoimmune disease. It is developing natural micronutrient molecules for treatment. Its leading candidates are on the path to Phase I trials.
Key Metrics
Founded Year
2017
Location
Kent, United Kingdom
Stage
Seed
Total Funding
$1.97M in 1 round
Latest Funding Round
Ranked
571st among 1970 active competitors
Employee Count
4 as on Aug 31, 2026
Legal entities associated with Azadyne
Azadyne is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
AZADYNE LTD CIN: 11740078 , United Kingdom, Active | Dec 23, 2018 | - | 3 (As on Dec 31, 2024) |
Sign up to download Azadyne's company profile
Azadyne's funding and investors
Azadyne has raised a total funding of $1.97M over 1 round. Its latest funding round was a Seed round on Mar 27, 2019 for $*****. 1 investor participated in its latest round. Azadyne has 4 institutional investors and 4 angel investors.
Here is the list of recent funding rounds of Azadyne:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 27, 2019 | 9099739 | Seed | 2912775 | 6980784 | 6557417 | 1440556 |
Access funding benchmarks and valuations. Sign up today!View details of Azadyne's funding rounds and investors
Azadyne's founders and board of directors
Founder? Claim ProfileHere are the details of Azadyne's key team members:
- Vincent Kelly: Co-Founder of Azadyne.
- Mike Southern: Co-Founder of Azadyne.
- Stephen Connon: Co-Founder of Azadyne.
View details of Azadyne's Founder profiles and Board Members
Azadyne's employee count trend
Azadyne has 4 employees as of Aug 26. Here is Azadyne's employee count trend over the years:
Uncover Azadyne's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Azadyne's Competitors and alternates
Top competitors of Azadyne include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Azadyne, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
2nd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
3rd | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
4th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
5th | Novogene Corporation 2011, Beijing (China), Series B | Provider of genomic services and solutions | $75M | 64/100 | |
6th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
7th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
8th | LifeMine Therapeutics 2016, Watertown (United States), Series E | Developer of novel drugs from fungi via genome mining and recombinant overexpression | $563M | 63/100 | |
9th | Dewpoint Therapeutics 2018, Boston (United States), Series D | Developer of small molecule based therapeutics | $364M | 62/100 | |
10th | One Biosciences 2020, Paris (France), Series A | Developer of single-cell therapeutics solutions to treat multiple health disorders | $22.4M | 62/100 | |
571st | Azadyne 2017, Kent (United Kingdom), Seed | Provider of therapeutic for autoimmune disease | $1.97M | 32/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Azadyne's competitors? Click here to see the top ones
Azadyne's Investments and acquisitions
Azadyne has made no investments or acquisitions yet.
Reports related to Azadyne
Here is the latest report on Azadyne's sector:
News related to Azadyne
•
•
Trinity College Dublin life sciences spin-out Azadyne raises €1.75mSilicon Republic•Mar 27, 2019•Azadyne
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Azadyne
Explore our recently published companies
- B.J. Slater - Unfunded company
- JK Contractors - United States based, Unfunded company
- Indio Solutions - Austin based, Unfunded company
- Veos Group - Zwevezele based, 1974 founded, Unfunded company
- TCQ Consulting - India based, 2024 founded, Unfunded company
- Peter McCuen - Unfunded company
